Intellia Therapeutics Inc Call to Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study Corporate Call Transcript
Good morning, and welcome to Intellia Therapeutics Investor Event to discuss the Interim Clinical Data from the Phase I Study of NTLA-2001. This conference is being recorded at the company's request and will be available on the company's website following the end of the call.
I will now turn the conference over to Lina Li, Director of Investor Relations at Intellia. Please proceed.
Thank you, operator, and good morning, everyone. Welcome to Intellia's investor event featuring interim data from our Phase I clinical trial of NTLA-2001. Saturday morning, we issued a press release detailing results presented at the 2021 Peripheral Nerve Society's Annual Meeting and published in the New England Journal of Medicine. This release and the accompanying presentation can be found on the Investors & Media section of Intellia's website at intelliatx.com. As a reminder, this call is being broadcast live, and a replay of the event will be archived on the company's website.
Before we begin, allow me
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |